{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:51Z","timestamp":1760028651763},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"DOI":"10.2146\/ajhp130005","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T22:07:37Z","timestamp":1379542057000},"page":"1716-1723","source":"Crossref","is-referenced-by-count":5,"title":["Safe and effective use of prostacyclins to treat pulmonary arterial hypertension"],"prefix":"10.1093","volume":"70","author":[{"given":"James C.","family":"Coons","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, and Clinical Pharmacist, Cardiology, University of Pittsburgh Medical Center, Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Clarke","sequence":"additional","affiliation":[{"name":"Cardiology, Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Wanek","sequence":"additional","affiliation":[{"name":"Cardiothoracic Intensive Care Unit, Cleveland Clinic, Cleveland, OH; at the time of writing he was Postgraduate Year 2 Critical Care Resident, Allegheny General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Bauer","sequence":"additional","affiliation":[{"name":"Anticoagulation, Allegheny General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather R.","family":"Bream-Rouwenhorst","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, and Clinical Assistant Professor, College of Pharmacy, University of Iowa, Iowa City"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041607520314300_b1-0701716","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2019041607520314300_b2-0701716","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.healun.2010.03.008","article-title":"Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey","volume":"29","author":"Kingman","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"2019041607520314300_b3-0701716","volume-title":"Ventavis (iloprost) package insert","year":"2012"},{"key":"2019041607520314300_b4-0701716","volume-title":"Tyvaso (treprostinil) package insert","year":"2011"},{"key":"2019041607520314300_b5-0701716","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"2019041607520314300_b6-0701716","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"2019041607520314300_b7-0701716","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2019041607520314300_b8-0701716","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2019041607520314300_b9-0701716","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","article-title":"Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies","volume":"48","author":"Voswinckel","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2019041607520314300_b10-0701716","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/0091270003261343","article-title":"Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2019041607520314300_b11-0701716","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0091270004264638","article-title":"Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2019041607520314300_b12-0701716","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.amjcard.2012.07.012","article-title":"Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension","volume":"110","author":"De Jesus Perez","year":"2012","journal-title":"Am J Cardiol"},{"key":"2019041607520314300_b13-0701716","volume-title":"Flolan (epoprostenol sodium) package insert","year":"2011"},{"key":"2019041607520314300_b14-0701716","volume-title":"Remodulin (treprostinil sodium) package insert","year":"2011"},{"key":"2019041607520314300_b15-0701716","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1753465812441849","article-title":"Targeted approaches to the treatment of pulmonary hypertension","volume":"6","author":"Fares","year":"2012","journal-title":"Ther Adv Respir Dis"},{"key":"2019041607520314300_b16-0701716","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"2019041607520314300_b17-0701716","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2019041607520314300_b18-0701716","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"2019041607520314300_b19-0701716","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","article-title":"Primary pulmonary hypertension","volume":"336","author":"Rubin","year":"1997","journal-title":"N Engl J Med"},{"key":"2019041607520314300_b20-0701716","volume-title":"Epoprostenol prescribing information","year":"2008"},{"key":"2019041607520314300_b21-0701716","volume-title":"Veletri (epoprostenol) first-generation prescribing information","year":"2011"},{"key":"2019041607520314300_b22-0701716","volume-title":"Veletri (epoprostenol) second-generation prescribing information","year":"2012"},{"key":"2019041607520314300_b23-0701716","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2146\/ajhp110687","article-title":"A new epoprostenol formulation for the treatment of pulmonary arterial hypertension","volume":"69","author":"Fuentes","year":"2012","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041607520314300_b24-0701716","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2019041607520314300_b25-0701716","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"2019041607520314300_b26-0701716","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"2019041607520314300_b27-0701716","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.healun.2010.06.013","article-title":"Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations","volume":"29","author":"Mathier","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"2019041607520314300_b28-0701716","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of iv treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"2019041607520314300_b29-0701716","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1086\/529552","article-title":"Bloodstream infections in patients given treatment with intravenous prostanoids","volume":"29","author":"Kallen","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2019041607520314300_b30-0701716","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1378\/chest.11-0245","article-title":"The effect of diluent pH on bloodstream infection rates in patients receiving iv treprostinil for pulmonary arterial hypertension","volume":"141","author":"Rich","year":"2012","journal-title":"Chest"},{"key":"2019041607520314300_b31-0701716","article-title":"Evaluation of the incidence of peripheral neuropathy associated with the use of intravenous epoprostenol and treprostinil for pulmonary hypertension","author":"Beranek"},{"key":"2019041607520314300_b32-0701716","first-page":"101","article-title":"Patient safety challenges in treprostinil therapy","volume":"17","author":"Roncesvalles","year":"2008","journal-title":"MedSurg Nursing"},{"key":"2019041607520314300_b33-0701716","unstructured":"CADD-Legacy ambulatory infusion pumps. St. Paul, MN: Smiths Medical MD, Inc.; 2007. www.smiths-medical.com\/education-resources\/downloads\/infusion-systems\/cadd-legacy-1-pump.html (accessed 2013 Apr 28)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/19\/1716\/28456515\/ajhp1716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:59:27Z","timestamp":1555415967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/19\/1716\/5112414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130005","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,10,1]]},"published":{"date-parts":[[2013,10,1]]}}}